Chugai Seiyaku Kabushiki Kaisha

Dainippon Sumitomo Pharma Co., Ltd.

International Institute of Cancer Immunology, Inc.

Sumitomo Pharma Co., Ltd.

Hideo Takasu

Haruo Sugiyama

Masashi Goto

Masashi Gotoh

Fumio Samizo

Naoto Kusunose

Masashi Nakatsuka

Megumi Nakamura

The present invention provides a novel tumor antigen peptide and its cancer vaccine, specifically, a peptide dimer wherein two peptide monomers consisting of 7-30 amino acids including at least one cysteine residue and being capable of producing a tumor antigen peptide are bound each other through a disulfide bond.

Dimerized peptide

HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients.

HLA-A24-restricted cancer antigen peptides

Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. Peptides which comprise an amino acid sequence of the formula: X-Y-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 4) wherein X represents Ser, Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe, or Asn, and Y represents Tyr or Met, and which has an activity to induce CTLs, polynucleotides encoding said peptides, cancer vaccines which comprise those peptides or polynucleotides as an active ingredient, and the like are disclosed.

WT1 substitution peptides

Growing community of inventors

Nishinomiya, Japan

Hideo Takasu